|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N07XX08
|
|
gptkbp:brand
|
gptkb:Vyndamax
gptkb:Vyndaqel
|
|
gptkbp:CASNumber
|
594839-88-0
|
|
gptkbp:chemicalClass
|
benzoxazole derivative
|
|
gptkbp:developer
|
gptkb:Pfizer
|
|
gptkbp:hasMolecularFormula
|
C14H7Cl2NO3
|
|
gptkbp:hasSMILES
|
Clc1ccc2c(c1)oc(cc2Cl)C(=O)Nc3ccccc3O
|
|
gptkbp:KEGGID
|
D09716
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
transthyretin stabilizer
|
|
gptkbp:molecularWeight
|
308.12 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
CHEMBL2105756
11236222
DB05382
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:glaucoma
diarrhea
abdominal pain
urinary tract infection
peripheral edema
vaginal infection
|
|
gptkbp:UNII
|
Y6O7T4EU0F
|
|
gptkbp:usedFor
|
gptkb:familial_amyloid_polyneuropathy
gptkb:transthyretin_amyloidosis
transthyretin amyloid cardiomyopathy
|
|
gptkbp:yearOfEMAApproval
|
2011
|
|
gptkbp:bfsParent
|
gptkb:transthyretin_amyloidosis
gptkb:wild-type_transthyretin_amyloidosis
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tafamidis
|